Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis Reply

被引：0

作者：

Vancheri, Carlo ^{[1
]}

Kreuter, Michael ^{[2
]}

Richeldi, Luca ^{[3
]}

Quaresma, Manuel ^{[4
]}

Stowasser, Susanne ^{[4
]}

Wuyts, Wim A. ^{[5
]}

机构：

[1] Univ Catania, Catania, Italy

[2] Heidelberg Univ, Heidelberg, Germany

[3] Fdn Policlin A Gemelli, Rome, Italy

[4] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[5] Univ Hosp Leuven, Leuven, Belgium

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 198卷 / 08期

关键词：

SAFETY;

D O I：

10.1164/rccm.201806-1116LE

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：1105 / 1106

页数：4

共 4 条

[1] An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) [J].

Costabel, Ulrich ;

Albera, Carlo ;

Lancaster, Lisa H. ;

Lin, Chin-Yu ;

Hormel, Philip ;

Hulter, Henry N. ;

Noble, Paul W. .

RESPIRATION, 2017, 94 (05) :408-415

[2] Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON [J].

Crestani, Bruno ;

Quaresma, Manuel ;

Kaye, Mitchell ;

Stansen, Wibke ;

Stowasser, Susanne ;

Kreuter, Michael .

EUROPEAN RESPIRATORY JOURNAL, 2017, 50

[3] SAFETY OF COMBINED PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS [J].

Flaherty, K. R. ;

Fell, C. D. ;

Huggins, J. T. ;

Nunes, H. ;

Sussman, R. ;

Valenzuela, C. ;

Petzinger, U. ;

Stauffer, J. L. ;

Gilberg, F. ;

Bengus, M. ;

Wijsenbeek, M. .

THORAX, 2017, 72 :A253-A254

[4]

Vancheri C, 2018, AM J RESP CRIT CARE, V197, P356, DOI 10.1164/rccm.201706-1301OC

← 1 →